About CLINUVEL

Dr Philippe Wolgen

MBA, MD

Chief Executive Officer, Managing Director

Having been recognised for his strategic mindset and meticulous business execution, Dr Wolgen has brought to the Company his international finance experience and professional contacts to European capital markets. As a former equity analyst, his in-depth analysis and expertise of the life science sector has been an asset to CLINUVEL. He held positions in private pharmaceutical companies in Europe, as MD of two medical centres in the UK and Israel, and consulted medical device companies. He has been instrumental in raising $86 million since 2006 for the funding of the current development program of SCENESSE® (afamelanotide 16mg).

Dr Wolgen holds an MBA from Columbia University NY and the London Business School. Trained as a craniofacial surgeon, Dr Wolgen holds an MD from the University of Utrecht, the Netherlands.

 

Latest Company Announcements

31 January 2017

Appendix 4C - Quarterly report

Quarterly report

Read More
23 December 2016

Appendix 3Y

Change of Director’s Interest Notice

Read More
20 December 2016

CLINUVEL Newsletter - December 2016

At the end of a calendar year we look back on plenty of activities and a solid financial performance by the CLINUVEL Group.

Read More
12 December 2016

Appendix 3Y

Change of Director’s Interest Notice

Read More
28 November 2016

Results of Meeting

AGM results

Read More
27 November 2016

Chair's Address to the Annual General Meeting

I would like to commence my address by saying it is always a pleasure to welcome familiar and a few new faces to the CLINUVEL Annual General meeting.

Read More

Quick Links